RECRUITINGINTERVENTIONAL
Study to Evaluate Music Therapy on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-HD)
Pilot Study Evaluating the Benefits of Music Therapy Combined With Conventional Treatment on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-HD)
About This Trial
The study is an open-label clinical trial evaluating whether music therapy combined with conventional management reduces irritability and impulsivity in 15 patients with early-stage Huntington's disease. This pilot study aims to show the interest of alternative non-pharmacological measures such as a digital music therapy tool, adapted to an audience of Huntington's patients, to help manage the psychobehavioral symptoms frequently observed in this affection, and to avoid breakdowns due to caregiver exhaustion.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age \>= 18 years
- Huntington disease genetically confirmed by the presence of at least 35 repeats of the CAG triplet in exon 1 of the HTT gene
- UHDRS (Unified Huntington's disease Rating Scale) score \<= 5 with a diagnostic confidence score =4
- Absence of significant cognitive impairment MoCA \>=24
- Stable drug therapy in the 28 days prior inclusion and during the study
- Without legal tutors or subordination
- Affiliated to a health insurance system as required by the French law on biomedical research
- Written willing to sign a consent form for participation in the study
Who Should NOT Join This Trial:
- Inability to give free and willing to sign a consent form for study participation
- Significant hearing impairment
- Participating to another study the day of enrollement
- Persons benefiting from enhanced protection, i.e.persons deprived of their liberty by a judicial or administrative decision, adults under legal and finally patients in a vital emergency situation.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age \>= 18 years
* Huntington disease genetically confirmed by the presence of at least 35 repeats of the CAG triplet in exon 1 of the HTT gene
* UHDRS (Unified Huntington's disease Rating Scale) score \<= 5 with a diagnostic confidence score =4
* Absence of significant cognitive impairment MoCA \>=24
* Stable drug therapy in the 28 days prior inclusion and during the study
* Without legal tutors or subordination
* Affiliated to a health insurance system as required by the French law on biomedical research
* Written informed consent for participation in the study
Exclusion Criteria:
* Inability to give free and informed consent for study participation
* Significant hearing impairment
* Participating to another study the day of enrollement
* Persons benefiting from enhanced protection, i.e.persons deprived of their liberty by a judicial or administrative decision, adults under legal and finally patients in a vital emergency situation.
Treatments Being Tested
OTHER
Music Intervention
Music therapy carried out with Music Care
Locations (1)
CHU Poitiers / CIC
Poitiers, France